Decision Expands Access to the Sonata® Treatment for Women Suffering from Uterine Fibroids, offering a Minimally Invasive Alternative to Hysterectomy or Myomectomy Redwood City, CA – December 17, 2024 – Gynesonics Inc., a medical device company focused on the development of minimally invasive
Gynesonics Announces New SMART OS™ Software Technology for Sonata® System Treatment of Uterine Fibroids
Revolutionizing Fibroid Treatment with Enhanced Precision, Control & Flexibility REDWOOD CITY, CA, September 26, 2024 – Gynesonics Inc., a medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today the launch of its new
Gynesonics® Reaches Milestone with 10,000th Patient Treatment with Sonata System
Cutting-edge incision-free solution advances standard of care for women with uterine fibroids REDWOOD CITY, CA, August 20, 2024 – Gynesonics®, Inc. a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine
Gynesonics Announces Key Executive Appointments to Further Accelerate and Expand Adoption of the Sonata Treatment
REDWOOD CITY, CA, March 19, 2024 – Gynesonics®, Inc., a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce several executive appointments for the positions of Chief Marketing and
Gynesonics Announces New Category 1 CPT Code for its Sonata Transcervical RF Ablation Procedure Used to Treat Uterine Fibroids
REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a privately-held women’s healthcare medical device company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that with the support of the American College of
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids Reaches Patient Milestones in the U.S. and Globally
REDWOOD CITY, Calif., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United
Gynesonics’ Incision-Free Sonata Procedure for the Treatment of Uterine Fibroids is Now Covered by UnitedHealthcare
REDWOOD CITY, CA, August 1, 2023 – Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure is now covered by UnitedHealthcare, effective August 1, 2023.
Gynesonics Names Industry Veteran Skip Baldino President and CEO, Announces $25M Financing to Expand Worldwide Commercialization
REDWOOD CITY, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Skip Baldino was appointed in early March to the role of President and Chief Executive